StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
300511.SZ$6.04-3.21%
Fair $6.04+0.0%

300511.SZ

Shanghai Xuerong Biotechnology Co.,Ltd.

Consumer Defensive / Farm ProductsShenzhen

$6.04

-0.20 (-3.21%)

Fairly Valued+0.0%Fair Value $6.04Fund rank 28/100 · Data gapFallback financials|
SA 29/D
F-Score: 7/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $109.7M · quality 45.3/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 28/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

29/100

D

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists. Revenue has declined for 2 consecutive years ROE is 1.8%, below the 5% threshold
Thesis & Journal · 300511.SZLocal privado en este navegador · Shanghai Xuerong Biotechnology Co.,Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$3.9B

P/E

19.5x

↑

EV/EBITDA

10.6x

↑

ROE

1.8%

↓

Gross Margin

13.6%

↓

Debt/Equity

0.76

↑
52-Week Range$6
$6$9

TradingView lightweight chart

300511.SZ price, volumen y niveles de valoración

Último $6.040Periodo -28.9%
Fair value: $6.040

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-5.0%

FCF CAGR

+91.8%

FCF margin

16.9%

FCF / Net income

11.29x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.99B · net income $29.8M · FCF $336.3M

2022-FY → 2025-FY

Gross margin

13.6%+2.9% pts

Operating margin

5.0%+0.6% pts

Net margin

1.5%+13.9% pts

FCF margin

16.9%+14.9% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.99B$1.99B$2.16B$2.57B$2.32B
Net Income$29.8M$29.8M$-617.1M$-188.1M$-287.2M
EBITDA$437.5M$437.5M$-144.3M$221.4M$53.7M
EPS0.050.05-1.24-0.38-0.59
Gross Margin13.6%13.6%3.6%8.4%10.7%
Operating Margin5.0%5.0%-4.6%-1.6%4.3%
Net Margin1.5%1.5%-28.5%-7.3%-12.4%
Balance Sheet
Debt/Equity0.760.762.291.441.01
Current Ratio0.660.66———
Cash Flow
Free Cash Flow$336.3M$336.3M$109.7M$-739.2M$47.7M
Returns
ROE1.8%1.8%-65.7%-12.1%-16.5%
Valuation
P/E19.4819.48———
EV/EBITDA10.6410.64—20.7283.57
P/B2.232.231.731.671.77
Growth & Yield
Revenue Growth-8.1%-8.1%-15.7%10.5%—
EPS Growth104.0%104.0%-226.3%35.6%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

120.5%

muy exigente

EPS terminal req.

$0.54

Spread vs growth

-16.5%

5Y implied EPS CAGR

67.0%

muy exigente

EPS terminal req.

$0.65

Spread vs growth

37.1%

10Y implied EPS CAGR

35.5%

muy exigente

EPS terminal req.

$1.04

Spread vs growth

68.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -12.2%

Total return

-12.2%

Start / end P/E

n/dx → n/dx

EPS bridge

-1.24 → 0.05

Residual

-12.2%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-12.2%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.